 |
 |
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Mar 01, 2024 |
Title |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation(s) |
40089460 |
|
Submission date |
Jan 10, 2024 |
Last update date |
Mar 19, 2025 |
Contact name |
Xiaoping Su |
E-mail(s) |
xsu1@mdanderson.org
|
Phone |
8328179083
|
Organization name |
MD Anderson Cancer Center
|
Street address |
7300 Brompton St, Apt 5633
|
City |
Houston |
State/province |
Texas |
ZIP/Postal code |
77025 |
Country |
USA |
|
|
Platforms (1) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
Samples (34)
|
GSM8010535 |
MOLM13 100 nM FHD-286 2 |
GSM8010536 |
MOLM13 Bulk RNA Control 1 |
GSM8010537 |
MOLM13 Bulk RNA Control 2 |
GSM8010538 |
MOLM13 Bulk RNA Control 3 |
GSM8010539 |
MOLM13 Bulk RNA 100 nM FHD-286 1 |
GSM8010540 |
MOLM13 Bulk RNA 100 nM FHD-286 2 |
GSM8010541 |
MOLM13 Bulk RNA 100 nM FHD-286 3 |
GSM8010542 |
MOLM13, Control, H3K27Ac |
GSM8010543 |
MOLM13, 100 nM FHD-286, H3K27Ac |
GSM8010544 |
MOLM13, Control, BRG1 |
GSM8010545 |
MOLM13, 100 nM FHD-286, BRG1 |
GSM8010546 |
MOLM13 Control, input |
GSM8010547 |
MOLM13, 100 nM FHD-286, input |
GSM8010548 |
DF16835, Control, BRM |
GSM8010549 |
DF16835, 100 nM FHD-286, BRM |
GSM8010550 |
DF16835, Control, H3K27Ac |
GSM8010551 |
DF16835, 100 nM FHD-286, H3K27Ac |
GSM8010552 |
DF16835, Control, input |
GSM8010553 |
DF16835, 100 nM FHD-286, input |
GSM8010554 |
AML323 Control scATAC Seq |
GSM8010555 |
AML323 100 nM FHD-286 scATAC Seq |
GSM8010556 |
AML336 Control scATAC Seq |
GSM8010557 |
AML336 100 nM FHD-286 scATAC Seq |
GSM8010558 |
AML340 Control scATAC Seq |
GSM8010559 |
AML340 100 nM FHD-286 scATAC Seq |
GSM8010560 |
AML323 Control scRNA Seq |
GSM8010561 |
AML323 100 nM FHD-286 scRNA Seq |
GSM8010562 |
AML336 Control scRNA Seq |
GSM8010563 |
AML336 100 nM FHD-286 scRNA Seq |
GSM8010564 |
AML340 Control scRNA Seq |
GSM8010565 |
AML340 100 nM FHD-286 scRNA Seq |
|
This SuperSeries is composed of the following SubSeries:
|
GSE252933 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk ATAC-Seq) |
GSE252934 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (Bulk RNA-Seq) |
GSE252935 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (ChIP-Seq) |
GSE252936 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scATAC-Seq) |
GSE252937 |
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor (scRNA-Seq) |
|
Relations |
BioProject |
PRJNA1063269 |
Supplementary file |
Size |
Download |
File type/resource |
GSE252938_RAW.tar |
11.0 Gb |
(http)(custom) |
TAR (of BROADPEAK, CSV, H5, MTX, NARROWPEAK, TBI, TSV) |
SRA Run Selector |
|
|
|
|
 |